Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) following a multistep international consensus process endorsed by 56 professional and patient organizations. The new name corrects a longstanding misnomer. The characteristic ovarian morphology reflects numerous arrested a...
M. B. Khomami, K. Hoeger, H. Huddleston et al.· American Journal of Obstetri...· 0 citations
Polyendocrine metabolic ovarian syndrome (PMOS) affects 8-13% of women across the lifespan. Those with PMOS have reduced quality of life and increased risk of co-morbidities including elevated weight, eating disorders, gestational diabetes, type 2 diabetes and cardiovascular disease. PMOS is a major population in clini...
Donna Vine, Lisa J. Moran, H. Teede et al.· Advances in Nutrition· 0 citations
In unselected populations, the majority of women with PCOS exhibit a normal BMI, in contrast to clinic-based cohorts, where obesity is markedly overrepresented, which indicates that longitudinal, population-based studies integrating multi-omic data are essential for unraveling BMI-related heterogeneity.
A. Bizuneh, C. Tay, Arul Earnest et al.· European Journal of Endocrin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.